Aeruginosin 98-B

Summary

Aeruginosin 98‑B is a non‑ribosomal cyanopeptide isolated from cyanobacteria. It has been used as a structural lead for the design of low‑molecular‑weight inhibitors of thrombin and related serine proteases. The compound itself is not an approved drug; research focuses on synthesising analogues that display in‑vitro enzyme inhibition.

Mechanism of Action

Cyanopeptides such as aeruginosin 98‑B belong to a class of serine‑protease inhibitors. They are thought to bind the catalytic pocket of enzymes like thrombin, interacting with the serine‑histidine‑aspartate triad and thereby blocking substrate cleavage. The exact binding mode of aeruginosin 98‑B has not been detailed in the cited literature, but its structural motifs serve as templates for analogues that act as competitive inhibitors of thrombin’s active site.

What the Research Shows

Three peer‑reviewed articles describe the use of aeruginosin 98‑B as a lead structure for new thrombin inhibitors. Radau and colleagues (2002) reported the synthesis of analogues RA‑1001 and RA‑1002, which inhibited thrombin with Ki values of 5.6 µM and 8.7 µM, respectively. A 2003 follow‑up expanded the series, emphasizing the marine cyanobacterial origin of the lead and describing the design of low‑molecular‑weight thrombin inhibitors (RA‑1001, RA‑1002). A third 2003 paper reported additional analogues (RA‑1005, RA‑1009) targeting broader serine proteases. All data are limited to in‑vitro enzyme assays; no animal or clinical studies were presented.

Reported Benefits

The primary benefit of aeruginosin 98‑B lies in its role as a scaffold for creating small‑molecule thrombin inhibitors. The reported analogues show micromolar inhibition of thrombin, suggesting potential for further optimisation toward antithrombotic agents. Because the compounds are low‑molecular‑weight, they may be more amenable to synthetic modification and drug‑like properties than larger peptide toxins.

Limitations of the Evidence

Evidence is confined to in‑vitro enzyme inhibition; the activity of the native aeruginosin 98‑B itself was not quantified. Reported Ki values are in the micromolar range, indicating only moderate potency. No pharmacokinetic, toxicity, or in‑vivo efficacy data are available, and the compounds have not progressed beyond early‑stage research. Consequently, therapeutic relevance remains speculative.

Safety Considerations

The abstracts provide no information on adverse effects, toxicity, or safety testing for aeruginosin 98‑B or its analogues. Cyanobacterial metabolites can be biologically active and sometimes toxic, so safety cannot be assumed. Until dedicated toxicology studies are performed, any use beyond laboratory research should be considered unsafe.

How It Is Administered

Aeruginosin 98‑B is a research‑grade compound studied only in vitro. No formulation or route of administration has been described in the literature. Any future application would require development of a suitable delivery system, but such work has not yet been reported.

Routes of Administration

No administration routes recorded yet.

Goals & Uses

• Protease inhibitionResearch ToolModerate

Contraindications

No contraindications recorded yet.

Adverse Effects

No adverse effects recorded yet.

Drug Interactions

No drug interactions recorded yet.

Population Constraints

No population constraints recorded yet.

Regulatory Status

No regulatory status recorded yet.

Evidence & Sources

• Cyanopeptide analogues: new lead structures for the design and synthesis of new thrombin inhibitors
  Journal ArticleLowRadau G, Stürzebecher J2002-01-01T00:00:00.000000Z
• New cyanopeptide-derived low molecular weight thrombin inhibitors
  Journal ArticleLowRadau G, Gebel J, Rauh D2003-01-01T00:00:00.000000Z
• New cyanopeptide-derived low molecular weight inhibitors of trypsin-like serine proteases
  Journal ArticleLowRadau G, Schermuly S, Fritsche A2003-01-01T00:00:00.000000Z

Frequently Asked Questions